5-chloro-N-(3-cyclopropyl-5-(((3R,5S)-3,5-dimethylpiperazin-1-yl)methyl)phenyl)-4-(6-methyl-1H-indol-3-yl)pyrimidin-2-amine | 2294874-49-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: 5-chloro-N-(3-cyclopropyl-5-(((3R,5S)-3,5-dimethylpiperazin-1-yl)methyl)phenyl)-4-(6-methyl-1H-indol-3-yl)pyrimidin-2-amine
• 英文别名: Tuspetinib；5-chloro-N-[3-cyclopropyl-5-[[(3S,5R)-3,5-dimethylpiperazin-1-yl]methyl]phenyl]-4-(6-methyl-1H-indol-3-yl)pyrimidin-2-amine
• CAS: 2294874-49-8
• 化学式: C₂₉H₃₃ClN₆
• 分子量: 501.074
• InChiKey: FZLSDZZNPXXBBB-KDURUIRLSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.8
• 重原子数：
  36
• 可旋转键数：
  6
• 环数：
  6.0
• sp3杂化的碳原子比例：
  0.38
• 拓扑面积：
  68.9
• 氢给体数：
  3
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  5-chloro-N-(3-cyclopropyl-5-(((3R,5S)-3,5-dimethylpiperazin-1-yl)methyl)phenyl)-4-(6-methyl-1H-indol-3-yl)pyrimidin-2-amine 在 盐酸 作用下， 以 水 、 丙酮 为溶剂， 生成 5-chloro-N-(3-cyclopropyl-5-(((3R,55)-3,5-dimethylpiperazine-1-yl)methyl)phenyl)-4-(6-methyl-1H-indole-3-yl)pyrimidine-2-amine hydrochloride
  参考文献：
  名称：

  WO2024096708A1

  摘要：

  公开号：

文献信息

• PHARMACEUTICAL COMPOSITION COMPRISING FLT3 INHIBITOR AND HYPOMETHYLATING AGENT FOR TREATING ACUTE MYELOID LEUKEMIA
  申请人：Hanmi Pharm. Co., Ltd.

  公开号：EP3928780A1

  公开（公告）日：2021-12-29

  Provided are a pharmaceutical composition for treating acute myeloid leukemia (AML), the pharmaceutical composition comprising an Fms-like tyrosine kinase (Fms-like tyrosine kinase-3: FLT3) inhibitor or a pharmaceutically acceptable salt or solvate thereof, and a hypomethylating agent (HMA) or a pharmaceutically acceptable salt or solvate thereof in a therapeutically effective combination, and a method of treating AML using the same.

  提供了一种用于治疗急性髓性白血病（AML）的药物组合物，该药物组合物包含一种Fms样酪氨酸激酶（Fms样酪氨酸激酶-3：FLT3）抑制剂或其药学上可接受的盐或溶液，以及一种低甲基化剂（HMA）或其药学上可接受的盐或溶液的治疗有效组合，并提供了一种使用该药物组合物治疗AML的方法。
• Pyrimidine compounds and pharmaceutical compositions for preventing or treating cancers including the same
  申请人：HANMI PHARM. CO., LTD.

  公开号：US10870639B2

  公开（公告）日：2020-12-22

  Provided are a pyrimidine compound represented by Formula 1, a method of preparing the compound, and a pharmaceutical use of the compound for the prevention or treatment of cancer.

  本发明提供了一种由式 1 表示的嘧啶化合物、制备该化合物的方法以及该化合物在预防或治疗癌症方面的药物用途。
• PYRIMIDINE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR PREVENTING OR TREATING CANCERS INCLUDING THE SAME
  申请人：HANMI PHARM. CO., LTD.

  公开号：US20200031806A1

  公开（公告）日：2020-01-30

  Provided are a pyrimidine compound represented by Formula 1, a method of preparing the compound, and a pharmaceutical use of the compound for the prevention or treatment of cancer.
• [EN] PHARMACEUTICAL COMPOSITION FOR TREATING ACUTE MYELOID LEUKEMIA CONTAINING FLT3 INHIBITOR AND MDM2 INHIBITOR<br/>[FR] COMPOSITION PHARMACEUTIQUE POUR LE TRAITEMENT DE LA LEUCÉMIE AIGUË MYÉLOÏDE CONTENANT UN INHIBITEUR DE FLT3 ET UN INHIBITEUR DE MDM2<br/>[KO] FLT3 저해제 및 MDM2 저해제를 포함하는 급성 골수성 백혈병 치료용 약학적 조성물
  申请人：HANMI PHARM IND CO LTD

  公开号：WO2021066443A1

  公开（公告）日：2021-04-08

  Fms-유사 티로신 키나아제(Fms-like tyrosine kinase-3: FLT3) 저해제, 이의 약제학적으로 허용되는 염, 또는 이의 용매화물과, 뮤린 더블 미닛 2(Murine double minute 2: MDM2) 저해제, 이의 약제학적으로 허용되는 염, 또는 이의 용매화물을 치료적 유효한 조합으로 포함하는, 급성 골수성 백혈병(AML) 치료용 약학적 조성물 및 이를 이용한 급성 골수성 백혈병의 치료 방법을 제공한다.